Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 17136208 | DNA BARCODING-BASED METHOD FOR RAPID IDENTIFICATION OF LYCIUM CHINENSIS | December 2020 | June 2024 | Abandon | 42 | 2 | 1 | No | No |
| 17125378 | DESIGNING PROBES FOR DEPLETING ABUNDANT TRANSCRIPTS | December 2020 | May 2024 | Abandon | 41 | 2 | 1 | Yes | No |
| 16952764 | METHODS AND COMPOSITIONS FOR EVALUATING GENETIC MARKERS | November 2020 | September 2023 | Allow | 34 | 2 | 1 | No | Yes |
| 17072449 | GENOTYPING EDITED MICROBIAL STRAINS | October 2020 | July 2024 | Abandon | 45 | 3 | 1 | No | No |
| 17039956 | QUANTIFICATION OF MOLECULES USING NUCLEIC ACID STRAND DISPLACEMENT DETECTION | September 2020 | July 2024 | Abandon | 46 | 2 | 1 | No | No |
| 17038496 | Methods for Treating and Detecting Sepsis in Humans | September 2020 | October 2023 | Abandon | 37 | 0 | 1 | No | No |
| 17005779 | COMPOSITIONS AND METHODS FOR DETECTION OF BK VIRUS | August 2020 | July 2023 | Allow | 34 | 1 | 1 | Yes | No |
| 16998690 | CANCER TREATMENTS AND METHODS OF SELECTING SAME | August 2020 | July 2023 | Abandon | 34 | 0 | 1 | No | No |
| 16986324 | METHOD AND SYSTEM FOR PREDICTING RECURRENCE AND NON-RECURRENCE OF MELANOMA USING SENTINEL LYMPH NODE BIOMARKERS | August 2020 | October 2021 | Abandon | 14 | 1 | 1 | No | No |
| 16939287 | HERITABLE EPIGENETIC MODIFICATIONS AS MARKERS OF CHEMOTHERAPY EXPOSURE | July 2020 | October 2022 | Abandon | 27 | 1 | 1 | Yes | No |
| 16938746 | METHODS AND COMPOSITION FOR HIGH THROUGHPUT SINGLE MOLECULE PROTEIN DETECTION SYSTEMS | July 2020 | March 2023 | Abandon | 32 | 1 | 1 | No | No |
| 16964390 | OLIGONUCLEOTIDE AND NUCLEIC ACID SYNTHESIS | July 2020 | November 2023 | Abandon | 40 | 2 | 1 | Yes | No |
| 16931813 | MOLECULAR GENETIC APPROACH TO TREATMENT AND DIAGNOSIS OF ALCOHOL AND DRUG DEPENDENCE | July 2020 | February 2022 | Allow | 19 | 1 | 1 | Yes | No |
| 16931303 | TREATING BREAST CANCER WITH HORMONE RECEPTOR MODULATORS | July 2020 | April 2023 | Abandon | 33 | 2 | 1 | No | No |
| 16961634 | FLUORESCENT NUCLEIC ACID NANOSTRUCTURE-GRAPHENE BIOSENSOR FOR NUCLEIC ACID DETECTION | July 2020 | March 2023 | Abandon | 32 | 2 | 1 | Yes | No |
| 16923803 | DIAGNOSING IDH1 RELATED SUBGROUPS AND TREATMENT OF CANCER | July 2020 | March 2022 | Abandon | 20 | 2 | 1 | Yes | No |
| 16918093 | QUANTITATIVE MICROBIAL COMMUNITY PROFILING USING MOLECULAR INVERSION PROBES WITH UNIQUE MOLECULAR IDENTIFIERS | July 2020 | March 2023 | Abandon | 33 | 2 | 1 | No | No |
| 16909278 | METHOD FOR DETECTING CYSTIC FIBROSIS | June 2020 | October 2024 | Abandon | 51 | 4 | 1 | Yes | No |
| 16954405 | METHOD FOR PURIFYING AND CONCENTRATING DNA IN FORENSIC SAMPLE BY USING SELECTIVE FILTRATION COLUMN | June 2020 | May 2022 | Abandon | 23 | 0 | 1 | No | No |
| 16772682 | METHODS AND COMPOSITIONS FOR THE AMPLIFICATION OF MRNA | June 2020 | February 2023 | Allow | 32 | 1 | 1 | No | No |
| 16899461 | WBP2 AS A CO-PROGNOSTIC FACTOR WITH HER2 FOR STRATIFICATION OF PATIENTS FOR TREATMENT | June 2020 | June 2023 | Abandon | 36 | 4 | 1 | No | No |
| 16887497 | Methods And Kits For Theranostic Applications | May 2020 | May 2024 | Abandon | 48 | 3 | 1 | No | No |
| 16887649 | PEPTIDE NUCLEIC ACID FUNCTIONALIZED HYDROGEL MICRONEEDLES FOR SAMPLING AND DETECTION OF INTERSTITIAL FLUID NUCLEIC ACIDS | May 2020 | January 2023 | Allow | 32 | 2 | 1 | Yes | No |
| 16767098 | ASSAYS FOR DETECTION OF ACUTE LYME DISEASE | May 2020 | November 2023 | Abandon | 41 | 2 | 1 | Yes | No |
| 16874831 | Biomarkers For Endometriosis | May 2020 | June 2022 | Abandon | 25 | 0 | 1 | No | No |
| 16861150 | BLOOD COLLECTION DEVICE FOR IMPROVED NUCLEIC ACID REGULATION | April 2020 | November 2023 | Abandon | 43 | 5 | 1 | No | No |
| 16840009 | SYSTEMS AND METHODS OF DIAGNOSING IDIOPATHIC PULMONARY FIBROSIS ON TRANSBRONCHIAL BIOPSIES USING MACHINE LEARNING AND HIGH DIMENSIONAL TRANSCRIPTIONAL DATA | April 2020 | November 2022 | Abandon | 32 | 0 | 1 | No | No |
| 16839339 | DETECTION OF GENOMIC SEQUENCES AND PROBE MOLECULES THEREFOR | April 2020 | August 2021 | Abandon | 16 | 2 | 1 | No | No |
| 16838403 | UPCONVERSION NANOPARTICLE-BASED MOLECULAR PROBES AND METHODS OF USE | April 2020 | February 2023 | Abandon | 35 | 2 | 1 | No | No |
| 16833406 | BIODEGRADATION OF TOXIC ORGANIC COMPOUNDS IN CONTAMINATED ENVIRONMENTS | March 2020 | October 2023 | Abandon | 42 | 2 | 1 | No | No |
| 16679161 | CHOOSING APPROPRIATE KINSHIP BETWEEN PATIENT AND EGG OR SPERM DONOR FOR MEDICALLY ASSISTED PREGNANCY | March 2020 | July 2023 | Abandon | 44 | 1 | 1 | No | No |
| 16649088 | RNA Quality Assay | March 2020 | September 2023 | Abandon | 42 | 2 | 1 | No | No |
| 16805445 | PREDICTING AGE-RELATED MACULAR DEGENERATION WITH SINGLE NUCLEOTIDE POLYMORPHISMS WITHIN OR NEAR THE GENES FOR COMPLEMENT COMPONENT C2, FACTOR B, PLEKHA1, HTRA1, PRELP, OR LOC387715 | February 2020 | December 2021 | Abandon | 22 | 1 | 1 | No | No |
| 16798137 | Plasma Microribonucleic Acids as Biomarkers for Endometriosis and Endometriosis-Associated Ovarian Cancer | February 2020 | May 2023 | Abandon | 39 | 4 | 1 | Yes | No |
| 16784696 | METHOD OF PREDICTING BREAST CANCER PROGNOSIS | February 2020 | May 2022 | Abandon | 27 | 3 | 1 | Yes | No |
| 16631980 | METHODS AND USES OF INFLAMMATORY BOWEL DISEASE BIOMARKERS | January 2020 | April 2023 | Abandon | 39 | 2 | 1 | No | No |
| 16744783 | URINE BIOMARKERS | January 2020 | January 2022 | Abandon | 24 | 1 | 1 | No | No |
| 16734854 | Identification of a JAK2 Mutation in Polycythemia Vera | January 2020 | July 2021 | Allow | 18 | 2 | 1 | Yes | No |
| 16713638 | DIAGNOSTIC AND THERAPEUTIC METHODS FOR IRAK4-MEDIATED DISORDERS AND CONDITIONS | December 2019 | October 2022 | Abandon | 34 | 3 | 1 | No | No |
| 16712102 | METHODS AND COMPOSITIONS FOR PREPARING RNA FROM A FIXED SAMPLE | December 2019 | July 2021 | Abandon | 19 | 2 | 1 | No | No |
| 16701688 | METHODS FOR RARE EVENT DETECTION | December 2019 | August 2022 | Abandon | 33 | 0 | 1 | No | No |
| 16618601 | Novel Circular RNA Biomarkers for Heart Failure | December 2019 | April 2023 | Abandon | 40 | 2 | 1 | Yes | No |
| 16617844 | INVESTIGATING TUMORAL AND TEMPORAL HETEROGENEITY THROUGH COMPREHENSIVE -OMICS PROFILING IN PATIENTS WITH METASTATIC TRIPLE NEGATIVE BREAST CANCER | November 2019 | August 2022 | Abandon | 32 | 1 | 1 | No | No |
| 16694851 | OLIGONUCLEOTIDE PROBES AND USES THEREOF | November 2019 | June 2021 | Abandon | 18 | 1 | 1 | No | No |
| 16614677 | METHODS FOR PERFORMING SPATIAL PROFILING OF BIOLOGICAL MOLECULES | November 2019 | July 2024 | Abandon | 56 | 4 | 1 | No | No |
| 16675488 | MOLECULAR PROFILING FOR CANCER | November 2019 | April 2021 | Abandon | 17 | 0 | 1 | No | No |
| 16670827 | METHODS, COMPOSITIONS AND SYSTEMS FOR CALIBRATING EPIGENETIC PARTITIONING ASSAYS | October 2019 | August 2024 | Abandon | 57 | 4 | 1 | No | No |
| 16597061 | MOLECULAR PROFILING FOR CANCER | October 2019 | April 2021 | Abandon | 18 | 0 | 1 | No | No |
| 16591278 | RENAL DISEASE TARGETS | October 2019 | April 2024 | Abandon | 55 | 3 | 1 | No | No |
| 16499630 | METHOD FOR DETECTING FLAVIVIRIDAE | September 2019 | April 2022 | Abandon | 31 | 0 | 1 | No | No |
| 16575228 | METHODS AND SYSTEMS FOR DETECTING TARGET NUCLEIC ACIDS | September 2019 | November 2021 | Abandon | 26 | 0 | 1 | No | No |
| 16492606 | MICROBIAL CONCENTRATION METHOD USING DIATOMITE AND NUCLEIC ACID EXTRACTION METHOD | September 2019 | February 2023 | Abandon | 41 | 2 | 1 | No | No |
| 16562727 | High-Throughput Aptamer Screening Assay | September 2019 | October 2022 | Abandon | 37 | 0 | 1 | No | No |
| 16556255 | METHODS OF DIAGNOSING DISEASES BY EXTRACELLULAR VESICLES AND USES THEREOF | August 2019 | October 2021 | Abandon | 26 | 2 | 1 | No | No |
| 16487849 | METHODS OF DIAGNOSING AND PROGNOSING CANCER | August 2019 | January 2023 | Abandon | 40 | 0 | 1 | No | No |
| 16526923 | Methods for Treating and Detecting Sepsis in Humans | July 2019 | August 2020 | Allow | 12 | 1 | 1 | Yes | No |
| 16481669 | METHOD FOR IDENTIFYING MITOCHONDRIAL DNA IN EXTRACELLULAR VESICLES AND TREATMENT OF MTDNA-RELATED DISORDERS AND CANCER | July 2019 | October 2022 | Abandon | 38 | 4 | 1 | No | No |
| 16514521 | MULTIPLEXED INSTRUMENT-FREE BAR-CHART SPINCHIP INTEGRATED WITH NANOPARTICLE-MEDIATED APTASENSORS FOR VISUAL QUANTITATIVE DETECTION OF MULTIPLE PATHOGENS | July 2019 | October 2023 | Abandon | 51 | 2 | 1 | No | No |
| 16513230 | SUPERVISED LEARNING METHODS FOR THE PREDICTION OF TUMOR RADIOSENSITIVITY TO PREOPERATIVE RADIOCHEMOTHERAPY | July 2019 | August 2021 | Abandon | 25 | 2 | 1 | No | No |
| 16460546 | METHOD FOR TREATING UROTHELIAL CARCINOMA | July 2019 | June 2021 | Allow | 24 | 2 | 1 | Yes | No |
| 16475038 | CHARACTERISTIC ANALYSIS METHOD AND CLASSIFICATION OF PHARMACEUTICAL COMPONENTS BY USING TRANSCRIPTOMES | June 2019 | June 2022 | Abandon | 36 | 1 | 1 | No | No |
| 16454755 | METHODS FOR DIAGNOSING ISCHEMIA | June 2019 | April 2022 | Allow | 34 | 2 | 1 | Yes | No |
| 16474164 | METHOD FOR SELECTING CELL | June 2019 | October 2023 | Abandon | 52 | 2 | 1 | Yes | No |
| 16472322 | TWO-PART MEDIATOR PROBE | June 2019 | May 2023 | Abandon | 47 | 2 | 1 | Yes | No |
| 16424976 | IDENTIFICATION OF A JAK2 MUTATION IN POLYCYTHEMIA VERA | May 2019 | October 2019 | Allow | 4 | 1 | 0 | No | No |
| 16424989 | ULTRASENSITIVE ASSAYS FOR DETECTION OF SHORT NUCLEIC ACIDS | May 2019 | July 2024 | Abandon | 60 | 4 | 1 | Yes | No |
| 16420307 | METHOD OF QUANTIFYING DNA | May 2019 | October 2023 | Abandon | 52 | 5 | 0 | Yes | No |
| 16462990 | BIOMARKERS FOR THE PROGNOSIS AND DIAGNOSIS OF CANCER | May 2019 | May 2021 | Abandon | 24 | 0 | 1 | No | No |
| 16411913 | COMPOSITIONS AND METHODS FOR CHEMICAL CLEAVAGE AND DEPROTECTION OF SURFACE-BOUND OLIGONUCLEOTIDES | May 2019 | May 2024 | Allow | 60 | 4 | 1 | Yes | Yes |
| 16348071 | MULTIPLEXED IMAGING USING MERFISH, EXPANSION MICROSCOPY, AND RELATED TECHNOLOGIES | May 2019 | March 2024 | Abandon | 58 | 4 | 1 | No | No |
| 16347874 | MATRIX IMPRINTING AND CLEARING | May 2019 | June 2023 | Abandon | 49 | 3 | 1 | Yes | No |
| 16346936 | Quantitative Cluster Analysis Method Of Target Protein By Using Next-Generation Sequencing And Use Thereof | May 2019 | December 2022 | Abandon | 44 | 0 | 1 | No | No |
| 16397705 | MEASURING METHOD AND MEASURING SYSTEM | April 2019 | October 2022 | Abandon | 41 | 0 | 1 | No | No |
| 16343852 | METHOD AND SYSTEM FOR PREDICTING RESPONSE OF A SUBJECT TO ANTIDEPRESSANT TREATMENT | April 2019 | June 2022 | Abandon | 37 | 1 | 1 | Yes | No |
| 16339173 | COMPUTER IMPLEMENTED DISCOVERY OF BIOMARKERS FOR BLOOD BRAIN BARRIER DISRUPTION | April 2019 | November 2022 | Abandon | 43 | 1 | 1 | No | No |
| 16365339 | SYSTEMS AND METHODS FOR NON-HORMONAL FEMALE CONTRACEPTIVE DRUG TARGET IDENTIFICATION AND PRIORITIZATION | March 2019 | July 2021 | Abandon | 28 | 0 | 1 | No | No |
| 16294864 | METHODS OF DETECTING NUCLEIC ACIDS IN INDIVIDUAL CELLS AND OF IDENTIFYING RARE CELLS FROM LARGE HETEROGENEOUS CELL POPULATIONS | March 2019 | November 2020 | Abandon | 20 | 3 | 1 | Yes | No |
| 16331112 | CLINICAL APPLICATION OF CELL FREE DNA TECHNOLOGIES TO NON-INVASIVE PRENATAL DIAGNOSIS AND OTHER LIQUID BIOPSIES | March 2019 | November 2023 | Abandon | 56 | 3 | 1 | No | No |
| 16292573 | METHODS AND SYSTEMS FOR DETECTING USUAL INTERSTITIAL PNEUMONIA | March 2019 | November 2021 | Abandon | 33 | 2 | 1 | Yes | No |
| 16326828 | Method of Detecting Active Tuberculosis Using Minimal Gene Signature | February 2019 | November 2023 | Abandon | 57 | 4 | 1 | Yes | No |
| 16274579 | HERITABLE EPIGENETIC MODIFICATIONS AS MARKERS OF CHEMOTHERAPY EXPOSURE | February 2019 | October 2020 | Abandon | 20 | 2 | 1 | Yes | No |
| 16272893 | METHODS AND MATERIALS FOR DETECTING GENE AMPLIFICATION | February 2019 | September 2020 | Abandon | 19 | 1 | 1 | No | No |
| 16259419 | CANCER PATIENT SELECTION FOR ADMINISTRATION OF WNT SIGNALING INHIBITORS USING RNF43 MUTATION STATUS | January 2019 | August 2020 | Abandon | 18 | 1 | 1 | No | No |
| 16250892 | Nucleic Acid Probe and Method of Detecting Genomic Fragments | January 2019 | April 2020 | Allow | 15 | 1 | 1 | Yes | No |
| 16250179 | METHOD OF PREDICTING BREAST CANCER PROGNOSIS | January 2019 | May 2020 | Abandon | 16 | 0 | 1 | No | No |
| 16070416 | METHOD OF DETECTING AND TREATING P. ACNES AND KIT THEREOF | January 2019 | September 2021 | Abandon | 38 | 0 | 1 | No | No |
| 16317791 | KRAS INHIBITOR FOR USE IN TREATING CANCER | January 2019 | February 2021 | Abandon | 25 | 0 | 1 | No | No |
| 16221941 | METHOD FOR DETECTING CYSTIC FIBROSIS | December 2018 | January 2021 | Abandon | 25 | 2 | 1 | No | No |
| 16206962 | Selection of Donors for Generation of Anti-Angiogenic Vaccine Compositions Including ValloVax | November 2018 | December 2021 | Abandon | 36 | 0 | 1 | No | No |
| 16206193 | COMPOSITIONS AND METHODS FOR PREPARING SHORT RNA MOLECULES AND OTHER NUCLEIC ACIDS | November 2018 | January 2022 | Abandon | 37 | 3 | 1 | No | No |
| 16305858 | THERMOSTABLE POLYMERASE INHIBITOR COMPOSITIONS AND METHODS | November 2018 | November 2021 | Allow | 36 | 0 | 1 | Yes | No |
| 16195274 | Exosome-Associated Microrna as a Diagnostic Marker | November 2018 | November 2021 | Abandon | 35 | 2 | 1 | No | Yes |
| 16301982 | MICRORNA EXPRESSION SIGNATURES FOR DOUBLECORTIN-LIKE KINASE 1 (DCLK1) ACTIVITY | November 2018 | December 2021 | Abandon | 37 | 1 | 1 | No | No |
| 16158669 | USE OF TRANSLATIONAL PROFILING TO IDENTIFY TARGET MOLECULES FOR THERAPEUTIC TREATMENT | October 2018 | July 2022 | Abandon | 45 | 2 | 1 | No | No |
| 16156576 | Probiotic Strains for Treating and/or Preventing Diarrhea | October 2018 | April 2020 | Allow | 18 | 1 | 1 | No | No |
| 16092358 | PLASMA-BASED DETECTION OF ANAPLASTIC LYMPHOMA KINASE (ALK) NUCLEIC ACIDS AND ALK FUSION TRANSCRIPTS AND USES THEREOF IN DIAGNOSIS AND TREATMENT OF CANCER | October 2018 | February 2022 | Abandon | 40 | 3 | 1 | No | No |
| 16153194 | DUAL LABELING METHODS FOR MEASURING CELLULAR PROLIFERATION | October 2018 | October 2023 | Abandon | 60 | 2 | 1 | No | No |
| 16087896 | PRE-TRANSPLANT TCR CLONALITY ASSESSMENT TO PREDICT POST-LIVER TRANSPLANT SURVIVAL | September 2018 | January 2023 | Abandon | 52 | 0 | 1 | No | No |
| 16087561 | MARKER FOR PREDICTING TREATMENT RESPONSE TO ANTI-CANCER AGENT IN SOLID CANCER PATIENTS | September 2018 | October 2020 | Abandon | 25 | 1 | 1 | No | No |
| 16136549 | Blood matrix metalloproteinase 9 (MMP9) is a predictive biomarker for cardiac diseases and disorders | September 2018 | December 2020 | Abandon | 27 | 1 | 1 | No | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner POHNERT, STEVEN C.
With a 36.4% reversal rate, the PTAB reverses the examiner's rejections in a meaningful percentage of cases. This reversal rate is above the USPTO average, indicating that appeals have better success here than typical.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 12.1% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.
✓ Appeals to PTAB show good success rates. If you have a strong case on the merits, consider fully prosecuting the appeal to a Board decision.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner POHNERT, STEVEN C works in Art Unit 1634 and has examined 871 patent applications in our dataset. With an allowance rate of 7.2%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 40 months.
Examiner POHNERT, STEVEN C's allowance rate of 7.2% places them in the 1% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.
On average, applications examined by POHNERT, STEVEN C receive 2.76 office actions before reaching final disposition. This places the examiner in the 77% percentile for office actions issued. This examiner issues more office actions than most examiners, which may indicate thorough examination or difficulty in reaching agreement with applicants.
The median time to disposition (half-life) for applications examined by POHNERT, STEVEN C is 40 months. This places the examiner in the 23% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.
Conducting an examiner interview provides a +14.3% benefit to allowance rate for applications examined by POHNERT, STEVEN C. This interview benefit is in the 52% percentile among all examiners. Recommendation: Interviews provide an above-average benefit with this examiner and are worth considering.
When applicants file an RCE with this examiner, 2.6% of applications are subsequently allowed. This success rate is in the 2% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.
This examiner enters after-final amendments leading to allowance in 3.8% of cases where such amendments are filed. This entry rate is in the 6% percentile among all examiners. Strategic Recommendation: This examiner rarely enters after-final amendments compared to other examiners. You should generally plan to file an RCE or appeal rather than relying on after-final amendment entry. Per MPEP § 714.12, primary examiners have discretion in entering after-final amendments, and this examiner exercises that discretion conservatively.
When applicants request a pre-appeal conference (PAC) with this examiner, 24.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 29% percentile among all examiners. Note: Pre-appeal conferences show below-average success with this examiner. Consider whether your arguments are strong enough to warrant a PAC request.
This examiner withdraws rejections or reopens prosecution in 42.1% of appeals filed. This is in the 9% percentile among all examiners. Of these withdrawals, 25.0% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner rarely withdraws rejections during the appeal process compared to other examiners. If you file an appeal, be prepared to fully prosecute it to a PTAB decision. Per MPEP § 1207, the examiner will prepare an Examiner's Answer maintaining the rejections.
When applicants file petitions regarding this examiner's actions, 99.4% are granted (fully or in part). This grant rate is in the 90% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.
Examiner's Amendments: This examiner makes examiner's amendments in 0.9% of allowed cases (in the 66% percentile). This examiner makes examiner's amendments more often than average to place applications in condition for allowance (MPEP § 1302.04).
Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.0% of allowed cases (in the 2% percentile). This examiner rarely issues Quayle actions compared to other examiners. Allowances typically come directly without a separate action for formal matters.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.